Loading clinical trials...
Loading clinical trials...
To Evaluate the Pharmacokinetics and Safety of Y-3 for Injection in Patients With Hepatic Insufficiency and Healthy Subjects
Conditions
Interventions
Y-3 for injection（40mg）
Start Date
July 10, 2025
Primary Completion Date
October 31, 2025
Completion Date
December 31, 2025
Last Updated
July 8, 2025
NCT06599697
NCT05910151
Lead Sponsor
Neurodawn Pharmaceutical Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions